Zydus Lifesciences announced on Monday that it has secured final approval from the US Food and Drug Administration (USFDA) to market Diltiazem Hydrochloride tablets, used for treating angina and high blood pressure, in the US.
The approval covers strengths of 30 mg, 60 mg, 90 mg, and 120 mg, the company said in a statement. Diltiazem Hydrochloride is prescribed for the management of chronic stable angina as well as angina caused by coronary artery spasm.
A calcium-channel blocker, Diltiazem helps relax blood vessels, reducing the heart’s workload while improving blood and oxygen flow to the heart muscle. The tablets will be manufactured at the company’s facility in Baddi, Himachal Pradesh.
According to IQVIA MAT June 2025 data, the product recorded annual sales of $13.9 million in the US market.